Freising-Weihenstephan, Germany (ots)
- Pieris AG, a
bio-pharmaceutical company developing Anticalins®, a novel class of
targeted human protein therapeutics, today announced successful
completion of a series of preclinical studies validating the use of
Anticalins® in ophthalmologic disease.
The studies reported by Pieris relate to PRS-055, an Anticalin®
specific for VEGF. VEGF is a key factor in the regulation of
neovascular permeability and is implicated in debilitating eye
diseases such as age-related macular degeneration (AMD),
proliferative diabetic retinopathy and retinopathy of prematurity.
Intravitreal injection of PRS-055 has been shown to inhibit
VEGF-induced breakdown of the blood-retinal barrier in a rabbit in
vivo model. The antagonistic effect of PRS-055 has been shown to be
of equivalent potency to that of the approved ophthalmology product
Lucentis® (ranibizumab; Genentech / Novartis).
"These exciting results have demonstrated that Anticalins® are
viable candidates as potent biotherapeutics for diseases of the eye"
said Dr Andreas Hohlbaum, Director of Science and Preclinical
Development of Pieris. "Based on the success of the PRS-055 program
to date, we are now selecting technologies for depot and/or
non-invasive drug delivery that will exploit the favorable size and
excellent stability characteristics of Anticalins®."
The preclinical data on PRS-055 will be presented on September
8th, 2007, at the IV. International Symposium of the German
Ophthalmological Society (DOG) in Baden-Baden, Germany.
Anticalin® is registered trademark of Pieris AG.
ots Originaltext: Pieris AG
Dr Andreas Hohlbaum
Director of Science and Preclinical Research
Further information is available at http://www.pieris-ag.com